PMID- 36015177
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230204
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 15
IP  - 8
DP  - 2022 Aug 21
TI  - Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of 
      Death Receptor 5.
LID - 10.3390/ph15081029 [doi]
LID - 1029
AB  - Death receptor 5 (DR5) is a membrane protein that mediates exogenous apoptosis. 
      Based on its function, it is considered to be a target for the treatment of 
      cancers including prostate cancer. It is encouraging to note that a number of 
      drugs targeting DR5 are now progressing to different stages of clinical trial 
      studies. We collected 38 active compounds that could produce anti-prostate-cancer 
      effects by modulating DR5, 28 of which were natural compounds and 10 of which 
      were synthetic compounds. In addition, 6 clinically used chemotherapeutic agents 
      have also been shown to promote DR5 expression and thus exert apoptosis-inducing 
      effects in prostate cancer cells. These compounds promote the expression of DR5, 
      thereby enhancing its function in inducing apoptosis. When these compounds were 
      used in combination with the natural ligand of DR5, the number of apoptotic cells 
      was significantly increased. These compounds are all promising for development as 
      anti-prostate-cancer drugs, while most of these compounds are currently being 
      evaluated for their anti-prostate-cancer effects at the cellular level and in 
      animal studies. A great deal of more in-depth research is needed to evaluate 
      whether they can be developed as drugs. We collected literature reports on small 
      molecules against prostate cancer through modulation of DR5 to understand the 
      current dynamics in this field and to evaluate the prospects of small molecules 
      against prostate cancer through modulation of DR5.
FAU - Gan, Xia
AU  - Gan X
AD  - Guangxi Zhuang Yao Medicine Center of Engineering and Technology, Guangxi 
      University of Chinese Medicine, 13 Wuhe Road, Qingxiu District, Nanning 530200, 
      China.
AD  - Institute of Marine Drugs, Guangxi University of Chinese Medicine, 13 Wuhe Road, 
      Qingxiu District, Nanning 530200, China.
FAU - Liu, Yonghong
AU  - Liu Y
AUID- ORCID: 0000-0001-8327-3108
AD  - Institute of Marine Drugs, Guangxi University of Chinese Medicine, 13 Wuhe Road, 
      Qingxiu District, Nanning 530200, China.
AD  - CAS Key Laboratory of Tropical Marine Bio-Resources and Ecology, Guangdong Key 
      Laboratory of Marine Materia Medica, South China Sea Institute of Oceanology, 
      Chinese Academy of Sciences, Guangzhou 510301, China.
FAU - Wang, Xueni
AU  - Wang X
AUID- ORCID: 0000-0001-9884-994X
AD  - Guangxi Zhuang Yao Medicine Center of Engineering and Technology, Guangxi 
      University of Chinese Medicine, 13 Wuhe Road, Qingxiu District, Nanning 530200, 
      China.
AD  - CAS Key Laboratory of Tropical Marine Bio-Resources and Ecology, Guangdong Key 
      Laboratory of Marine Materia Medica, South China Sea Institute of Oceanology, 
      Chinese Academy of Sciences, Guangzhou 510301, China.
LA  - eng
GR  - AD20159033/Specific Research Project of Guangxi for Research Bases and Talents/
GR  - Y.H. Liu/Special Fund for Bagui Scholars of Guangxi/
PT  - Journal Article
PT  - Review
DEP - 20220821
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC9413322
OTO - NOTNLM
OT  - chemotherapeutic agents
OT  - death receptor 5
OT  - natural compounds
OT  - prostate cancer
OT  - synthesized compounds
COIS- The authors declare no conflict of interest.
EDAT- 2022/08/27 06:00
MHDA- 2022/08/27 06:01
PMCR- 2022/08/21
CRDT- 2022/08/26 01:41
PHST- 2022/07/30 00:00 [received]
PHST- 2022/08/15 00:00 [revised]
PHST- 2022/08/19 00:00 [accepted]
PHST- 2022/08/26 01:41 [entrez]
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/08/27 06:01 [medline]
PHST- 2022/08/21 00:00 [pmc-release]
AID - ph15081029 [pii]
AID - pharmaceuticals-15-01029 [pii]
AID - 10.3390/ph15081029 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2022 Aug 21;15(8):1029. doi: 10.3390/ph15081029.